Journal: Materials Today Bio

Article Title: One-step fabrication of 3D-aligned human skeletal muscle tissue and measurement of contractile force for preclinical drug testing

doi: 10.1016/j.mtbio.2025.101456

Figure Lengend Snippet: Reduction of fatigue resistance (ability to maintain a tetanus contraction) in the 3D-aligned muscle tissue after treatment with clenbuterol. (a) Change in the highest contractile force in single tetanus contractions by adding clenbuterol at different concentrations (final concentration: 0 μM, 0.1 μM, 10 μM, 50 μM, and 100 μM). Contractile forces were normalized by the force before the addition of clenbuterol (n = 3). A significant decrease was observed between the 0 μM clenbuterol group and the 100 μM clenbuterol group ( ∗P < 0.05, Dunnett's test). (b) Profiles of a tetanus contraction at 0 and 20 min after adding clenbuterol (final concentration: 0.1 μM, 10 μM, 50 μM, and 100 μM). EPS (frequency: 15 Hz) was applied to produce tetanus contractions in the same tissue samples at 0 and 20 min after adding clenbuterol. (c) Force change in single tetanus contractions (the ability to maintain a tetanus contraction) with clenbuterol at different concentrations (0 μM, 0.1 μM, and 10 μM) (n = 3). Only in the 10 μM clenbuterol group, there was a significant difference between before and after the addition of clenbuterol ( ∗P < 0.05, Student's t-test). Contractile forces shown in (a) and (c) were obtained from measurements in three different tissue samples.

Article Snippet: The contractile force measurement device was originally developed by our group, and partly customized by NIHON KOHDEN Corporation (Tokyo, Japan) [ ].

Techniques: Concentration Assay

Journal: Materials Today Bio

Article Title: One-step fabrication of 3D-aligned human skeletal muscle tissue and measurement of contractile force for preclinical drug testing

doi: 10.1016/j.mtbio.2025.101456

Figure Lengend Snippet: Contractile force measurement of human muscle tissues stimulated electrically and chemically. (a) Photographs of muscle tissue suspended on a load cell for contractile force measurement. Two electrodes were immersed in a culture medium (phenol red free) to electrically stimulate the muscle tissue. (b) Representative profile of contractile force produced by muscle tissue at various EPS frequencies (0.5, 1, 5, and 15 Hz). (c) Contractile forces of muscle tissues generated by twitch and tetanus contractions. These tissues were cultured in a differentiation medium containing SB431542 at various concentrations (0, 5, 10, 25, or 50 μM). Contractile forces of six different tissues were measured at each concentration (n = 6). Significant differences were observed between 0 μM and 10 μM in twitch, and between 0 μM versus 5 and 10 μM in tetanus (∗∗ P < 0.01, Dunnett's test). (d) Representative contractile force profile of a muscle tissue chemically stimulated by the addition of ACh. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: The contractile force measurement device was originally developed by our group, and partly customized by NIHON KOHDEN Corporation (Tokyo, Japan) [ ].

Techniques: Produced, Generated, Cell Culture, Concentration Assay

Journal: Materials Today Bio

Article Title: One-step fabrication of 3D-aligned human skeletal muscle tissue and measurement of contractile force for preclinical drug testing

doi: 10.1016/j.mtbio.2025.101456

Figure Lengend Snippet: Effects of ryanodine on the contractility of the engineered muscle tissue. (a) Upper: Representative profile of contractile force generated by EPS (1.5 Hz) for 10 min with ryanodine (5.0 μM). Lower: Contractile force profiles just after and 10 min after the addition of ryanodine (final concentration: 5.0 μM). (b) Change in contractile forces reduced by the addition of ryanodine at different concentrations (0.5 μM, 1.0 μM, and 5.0 μM) (n = 3). Significant differences were observed in comparison with the groups without the addition of ryanodine (0 μM), and in comparing the low (0.5 μM and 1.0 μM) and high concentration groups (5.0 μM) ( ∗P < 0.05, Games-Howell test). Contractile forces were normalized by the force at 0 min. (c) Profiles of tetanus contractions (EPS: 15 Hz) before (0 min) and after (10 min) the addition of ryanodine (final concentration: 5.0 μM). (d) Change in contractile forces of tetanus contraction by adding ryanodine at different concentrations (final concentration: 0.5 μM, 1.0 μM, and 5.0 μM). Contractile forces were normalized by the force before the addition of ryanodine (n = 3). The 5.0 μM ryanodine group was significantly lower than the other two concentration groups ( ∗P < 0.05, Tukey HSD). Contractile forces shown in (b) and (d) were obtained from measurements of three different tissue samples.

Article Snippet: The contractile force measurement device was originally developed by our group, and partly customized by NIHON KOHDEN Corporation (Tokyo, Japan) [ ].

Techniques: Generated, Concentration Assay, Comparison

Journal: Materials Today Bio

Article Title: One-step fabrication of 3D-aligned human skeletal muscle tissue and measurement of contractile force for preclinical drug testing

doi: 10.1016/j.mtbio.2025.101456

Figure Lengend Snippet: Effects of dantrolene on the contractility of the engineered muscle tissue. (a) Upper: Representative profile of contractile force generated by EPS (1.5 Hz) with dantrolene (50.0 μM). Lower: Contractile force profiles in twitch contractions just after (0 min) and 10 min after the addition of dantrolene (final concentration: 50.0 μM). (b) Change in contractile forces reduced by the addition of dantrolene at different concentrations (12.5 μM, 25.0 μM, and 50.0 μM) (n = 3). Significant decreases in contractile force were observed between the low concentration groups (0 μM and 12.5 μM) versus the high concentration groups (25.0 μM and 50.0 μM) ( ∗P < 0.05, Games-Howell test). Contractile forces were normalized by the force at 0 min. (c) Profiles of tetanus contractions (EPS: 15 Hz) before (0 min) and after (10 min) the addition of dantrolene (final concentration: 50.0 μM). (d) Change in contractile force of tetanus contraction by adding dantrolene at different concentrations (final concentration: 12.5 μM, 25.0 μM, and 50.0 μM). Contractile forces were normalized by the force before the addition of dantrolene (n = 3). Statistically significant differences were not observed between the groups (one-way ANOVA). Contractile forces shown in (b) and (d) were obtained from measurements of three different tissue samples.

Article Snippet: The contractile force measurement device was originally developed by our group, and partly customized by NIHON KOHDEN Corporation (Tokyo, Japan) [ ].

Techniques: Generated, Concentration Assay

Journal: Materials Today Bio

Article Title: One-step fabrication of 3D-aligned human skeletal muscle tissue and measurement of contractile force for preclinical drug testing

doi: 10.1016/j.mtbio.2025.101456

Figure Lengend Snippet: Reduction in contractile force of twitch contraction by treatment with clenbuterol. (a) Twitch contractions of the 3D-aligned muscle tissue at 0 and 20 min after the addition of clenbuterol (final concentration: 0.1 μM and 100 μM). (b) Change in contractile forces generated by EPS (1 Hz) for 20 min with clenbuterol (final concentration: 0 μM, 0.1 μM, 10 μM, 50 μM, and 100 μM). Contractile forces were normalized by the force just after (0 min) the addition of clenbuterol (n = 3). The contractile force was significantly lower in the high concentration groups (50 μM and 100 μM) compared to the low concentration groups (0 μM, 0.1 μM, and 10 μM), moreover, the results of the100 μM clenbuterol group were observed to be much lower than in the 50 μM clenbuterol group ( ∗P < 0.05, Games-Howell test). (c) Reduction in contractile force at 20 min after the addition of clenbuterol (final concentration: 0 μM, 0.1 μM, 10 μM, 50 μM, and 100 μM). Contractile forces were normalized by the force just after the addition of clenbuterol (n = 3). Significant decreases were observed between the no clenbuterol group (0 μM) versus the 50 μM and 100 μM clenbuterol groups ( ∗P < 0.05, Dunnett's test). Contractile forces shown in (b) and (c) were obtained from measurements of three different tissue samples.

Article Snippet: The contractile force measurement device was originally developed by our group, and partly customized by NIHON KOHDEN Corporation (Tokyo, Japan) [ ].

Techniques: Concentration Assay, Generated

Journal: Materials Today Bio

Article Title: One-step fabrication of 3D-aligned human skeletal muscle tissue and measurement of contractile force for preclinical drug testing

doi: 10.1016/j.mtbio.2025.101456

Figure Lengend Snippet: Schematic illustration of the one-step fabrication of aligned muscle tissue with adaptor designed for contractile force measurement.

Article Snippet: The contractile force measurement device was originally developed by our group, and partly customized by NIHON KOHDEN Corporation (Tokyo, Japan) [ ].

Techniques:

Journal: Materials Today Bio

Article Title: One-step fabrication of 3D-aligned human skeletal muscle tissue and measurement of contractile force for preclinical drug testing

doi: 10.1016/j.mtbio.2025.101456

Figure Lengend Snippet: One-step fabrication of a human muscle tissue composed of aligned myofibers in a fibrin-based gel adjusted for contractile force measurement. (a) A fibrin-based gel was formed with a customized adaptor to attach a contractile force measurement device, and shrunken gels, with and without cells, were released from the anchoring parts (indicated as dotted lines) by cutting both sides of the gel. (b) Fibrin-based gel with cells before and after release from the hanging adaptor. The lengths of the gel are indicated by arrows. (c–h) Fluorescence images of aligned myofibers in the gel after 7 days of differentiation induction [(c) green: MHC, blue: nuclei; (d, e) green: α-actinin, blue: nuclei; (f, g) green: MHC, red: laminin; (h) red: dystrophin]. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: The contractile force measurement device was originally developed by our group, and partly customized by NIHON KOHDEN Corporation (Tokyo, Japan) [ ].

Techniques: Fluorescence

Journal: Scientific Reports

Article Title: Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes

doi: 10.1038/s41598-018-33293-2

Figure Lengend Snippet: Contractility of hiPSC-cardiomyocytes under High Glucose Condition and Empagliflozin. ( A ) Representative tracings of cell changes. (B) Percentage cell shortening; (C) Maximal velocity of cell shortening and (D) Maximal velocity of cell re-lengthening. Abbreviations: NG: normal glucose; HG: high glucose; HG + E: high glucose and empagliflozin; and HG, HG + E: high glucose for 7 days followed with empagliflozin. * p < 0.05; ** p < 0.01.

Article Snippet: Contractility and intracellular calcium transient of hiPSC-derived cardiomyocytes were evaluated with the IonOptix myocyte calcium and contractility system (IonOptix, Milton, MA) .

Techniques: